Literature DB >> 34915451

Pre- and post-treatment image-based dosimetry in90Y-microsphere radioembolization using the TOPAS Monte Carlo toolkit.

Alejandro Bertolet1, Eric Wehrenberg-Klee2, Mislav Bobić1,3, Clemens Grassberger1, Joseph Perl4, Harald Paganetti1, Jan Schuemann1.   

Abstract

Objective. To evaluate the pre-treatment and post-treatment imaging-based dosimetry of patients treated with 90Y-microspheres, including accurate estimations of dose to tumor, healthy liver and lung. To do so, the Monte Carlo (MC) TOPAS platform is in this work extended towards its utilization in radionuclide therapy.Approach. Five patients treated at the Massachusetts General Hospital were selected for this study. All patients had data for both pre-treatment SPECT-CT imaging using 99mTc-MAA as a surrogate of the 90Y-microspheres treatment and SPECT-CT imaging immediately after the 90Y activity administration. Pre- and post-treatment doses were computed with TOPAS using the SPECT images to localize the source positions and the CT images to account for tissue inhomoegeneities. We compared our results with analytical calculations following the voxel-based MIRD scheme.Main results. TOPAS results largely agreed with the MIRD-based calculations in soft tissue regions: the average difference in mean dose to the liver was 0.14 Gy GBq-1(2.6%). However, dose distributions in the lung differed considerably: absolute differences in mean doses to the lung ranged from 1.2 to 6.3 Gy GBq-1and relative differences from 153% to 231%. We also found large differences in the intra-hepatic dose distributions between pre- and post-treatment imaging, but only limited differences in the pulmonary dose.Significance. Doses to lung were found to be higher using TOPAS with respect to analytical calculations which may significantly underestimate dose to the lung, suggesting the use of MC methods for 90Y dosimetry. According to our results, pre-treatment imaging may still be representative of dose to lung in these treatments.
© 2021 Institute of Physics and Engineering in Medicine.

Entities:  

Keywords:  90Y microsphere; internal dosimetry; radioembolization; radionuclides; topas

Mesh:

Substances:

Year:  2021        PMID: 34915451      PMCID: PMC8729171          DOI: 10.1088/1361-6560/ac43fd

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  45 in total

1.  A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions.

Authors:  N Lanconelli; M Pacilio; S Lo Meo; F Botta; A Di Dia; A Torres Aroche; M A Coca Pérez; M Cremonesi
Journal:  Phys Med Biol       Date:  2012-01-21       Impact factor: 3.609

Review 2.  Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review.

Authors:  Chadwick L Wright; Jeff D Werner; Jerry M Tran; Vanessa L Gates; Ali A Rikabi; Manisha H Shah; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2012-05       Impact factor: 3.464

3.  Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies.

Authors:  William A Dezarn; Jeffery T Cessna; Larry A DeWerd; Wenzheng Feng; Vanessa L Gates; James Halama; Andrew S Kennedy; Subir Nag; Mehrdad Sarfaraz; Varun Sehgal; Reed Selwyn; Michael G Stabin; Bruce R Thomadsen; Lawrence E Williams; Riad Salem
Journal:  Med Phys       Date:  2011-08       Impact factor: 4.071

4.  Validation of the TOPAS Monte Carlo toolkit for HDR brachytherapy simulations.

Authors:  Francisco Berumen; Yunzhi Ma; José Ramos-Méndez; Joseph Perl; Luc Beaulieu
Journal:  Brachytherapy       Date:  2021-04-22       Impact factor: 2.362

5.  Validation of a dose-point kernel convolution technique for internal dosimetry.

Authors:  H B Giap; D J Macey; J E Bayouth; A L Boyer
Journal:  Phys Med Biol       Date:  1995-03       Impact factor: 3.609

6.  The MIRD Schema: from organ to cellular dimensions.

Authors:  R W Howell
Journal:  J Nucl Med       Date:  1994-03       Impact factor: 10.057

7.  VIDA: a voxel-based dosimetry method for targeted radionuclide therapy using Geant4.

Authors:  Susan D Kost; Yuni K Dewaraja; Richard G Abramson; Michael G Stabin
Journal:  Cancer Biother Radiopharm       Date:  2015-01-16       Impact factor: 3.099

8.  Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.

Authors:  Riad Salem; Robert Lewandowski; Carol Roberts; James Goin; Kenneth Thurston; Marwan Abouljoud; Angi Courtney
Journal:  J Vasc Interv Radiol       Date:  2004-04       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.